In a report released today, Lorenzo Biasio from Credit Suisse maintained a Buy rating on Mylan Inc (MYL), with a price target of $37. The company’s shares opened today at $28.11, close to its 52-week low of $26.
According to TipRanks.com, Biasio is ranked #1436 out of 5228 analysts.
Currently, the analyst consensus on Mylan Inc is a Moderate Buy with an average price target of $35.69, a 27.0% upside from current levels. In a report issued on February 27, BTIG also maintained a Buy rating on the stock with a $35 price target.
See today’s analyst top recommended stocks >>
Mylan Inc’s market cap is currently $14.13B and has a P/E ratio of 40.28. The company has a Price to Book ratio of 1.16.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe, Rest of World, and Corporate or Other.
